Mylab Discovery Solutions, a Pune-based company, has recently introduced a rapid point-of-care test called PathoCatch Sickle Cell Rapid Test for early detection of sickle cell anemia, a genetic blood disorder. This launch is significant as sickle cell anemia poses a major public health challenge in India, with the country estimated to have the second highest burden of the disease globally. It is believed that around 18 million people in India carry the sickle cell trait, and approximately 1.4 million individuals suffer from sickle cell disease. Detecting the condition early and providing timely intervention is crucial for effectively managing the complications associated with sickle cell anemia.
Traditionally, diagnosing sickle cell anemia has been a time-consuming and labor-intensive process. It involved collecting blood samples, transporting them to a laboratory, and conducting analysis by skilled technicians. This lengthy process often resulted in delayed diagnosis and treatment, leading to higher morbidity and mortality rates among patients. However, Mylab’s PathoCatch Sickle Cell Rapid Test utilizes cutting-edge technology to detect the presence of abnormal hemoglobin in a small blood sample within minutes. One of the key advantages of this test is that it can be performed by healthcare professionals without the need for laboratory equipment.
By offering a rapid and convenient testing solution, Mylab aims to improve the early detection of sickle cell anemia and enable timely interventions, ultimately reducing the burden of the disease in India. This innovation has the potential to positively impact the lives of millions of individuals affected by sickle cell anemia by facilitating faster and more accessible diagnosis, leading to improved management and outcomes for patients.
